235 related articles for article (PubMed ID: 20426425)
1. Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237.
Sloane DA; Trikic MZ; Chu ML; Lamers MB; Mason CS; Mueller I; Savory WJ; Williams DH; Eyers PA
ACS Chem Biol; 2010 Jun; 5(6):563-76. PubMed ID: 20426425
[TBL] [Abstract][Full Text] [Related]
2. Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence.
Liu Y; Hawkins OE; Su Y; Vilgelm AE; Sobolik T; Thu YM; Kantrow S; Splittgerber RC; Short S; Amiri KI; Ecsedy JA; Sosman JA; Kelley MC; Richmond A
EMBO Mol Med; 2013 Jan; 5(1):149-66. PubMed ID: 23180582
[TBL] [Abstract][Full Text] [Related]
3. Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks.
Scutt PJ; Chu ML; Sloane DA; Cherry M; Bignell CR; Williams DH; Eyers PA
J Biol Chem; 2009 Jun; 284(23):15880-93. PubMed ID: 19359241
[TBL] [Abstract][Full Text] [Related]
4. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
Görgün G; Calabrese E; Hideshima T; Ecsedy J; Perrone G; Mani M; Ikeda H; Bianchi G; Hu Y; Cirstea D; Santo L; Tai YT; Nahar S; Zheng M; Bandi M; Carrasco RD; Raje N; Munshi N; Richardson P; Anderson KC
Blood; 2010 Jun; 115(25):5202-13. PubMed ID: 20382844
[TBL] [Abstract][Full Text] [Related]
5. Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen.
Kwiatkowski N; Deng X; Wang J; Tan L; Villa F; Santaguida S; Huang HC; Mitchison T; Musacchio A; Gray N
ACS Chem Biol; 2012 Jan; 7(1):185-96. PubMed ID: 21992004
[TBL] [Abstract][Full Text] [Related]
6. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.
Qi W; Cooke LS; Liu X; Rimsza L; Roe DJ; Manziolli A; Persky DO; Miller TP; Mahadevan D
Biochem Pharmacol; 2011 Apr; 81(7):881-90. PubMed ID: 21291867
[TBL] [Abstract][Full Text] [Related]
7. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma.
Brockmann M; Poon E; Berry T; Carstensen A; Deubzer HE; Rycak L; Jamin Y; Thway K; Robinson SP; Roels F; Witt O; Fischer M; Chesler L; Eilers M
Cancer Cell; 2013 Jul; 24(1):75-89. PubMed ID: 23792191
[TBL] [Abstract][Full Text] [Related]
8. Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.
Mohan P; Castellsague J; Jiang J; Allen K; Chen H; Nemirovsky O; Spyra M; Hu K; Kluwe L; Pujana MA; Villanueva A; Mautner VF; Keats JJ; Dunn SE; Lazaro C; Maxwell CA
Oncotarget; 2013 Jan; 4(1):80-93. PubMed ID: 23328114
[TBL] [Abstract][Full Text] [Related]
9. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
Zhou N; Singh K; Mir MC; Parker Y; Lindner D; Dreicer R; Ecsedy JA; Zhang Z; Teh BT; Almasan A; Hansel DE
Clin Cancer Res; 2013 Apr; 19(7):1717-28. PubMed ID: 23403633
[TBL] [Abstract][Full Text] [Related]
10. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Gontarewicz A; Balabanov S; Keller G; Colombo R; Graziano A; Pesenti E; Benten D; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
Blood; 2008 Apr; 111(8):4355-64. PubMed ID: 18268096
[TBL] [Abstract][Full Text] [Related]
12. Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro.
Tomita M; Mori N
Cancer Sci; 2010 May; 101(5):1204-11. PubMed ID: 20180813
[TBL] [Abstract][Full Text] [Related]
13. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of specific binding between Aurora A and TPX2 by molecular dynamics simulations.
Cheng Y; Zhang F; Chen Q; Gao J; Cui W; Ji M; Tung CH
J Chem Inf Model; 2011 Oct; 51(10):2626-35. PubMed ID: 21919471
[TBL] [Abstract][Full Text] [Related]
15. The Aurora A and Aurora B protein kinases: a single amino acid difference controls intrinsic activity and activation by TPX2.
Eyers PA; Churchill ME; Maller JL
Cell Cycle; 2005 Jun; 4(6):784-9. PubMed ID: 15908779
[TBL] [Abstract][Full Text] [Related]
16. Molecular distinctions between Aurora A and B: a single residue change transforms Aurora A into correctly localized and functional Aurora B.
Hans F; Skoufias DA; Dimitrov S; Margolis RL
Mol Biol Cell; 2009 Aug; 20(15):3491-502. PubMed ID: 19494039
[TBL] [Abstract][Full Text] [Related]
17. Tripolin A, a novel small-molecule inhibitor of aurora A kinase, reveals new regulation of HURP's distribution on microtubules.
Kesisova IA; Nakos KC; Tsolou A; Angelis D; Lewis J; Chatzaki A; Agianian B; Giannis A; Koffa MD
PLoS One; 2013; 8(3):e58485. PubMed ID: 23516487
[TBL] [Abstract][Full Text] [Related]
18. Molecular dynamics and free energy studies on Aurora kinase A and its mutant bound with MLN8054: insight into molecular mechanism of subtype selectivity.
Yang Y; Shen Y; Li S; Jin N; Liu H; Yao X
Mol Biosyst; 2012 Nov; 8(11):3049-60. PubMed ID: 22990663
[TBL] [Abstract][Full Text] [Related]
19. Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.
McLaughlin J; Markovtsov V; Li H; Wong S; Gelman M; Zhu Y; Franci C; Lang D; Pali E; Lasaga J; Low C; Zhao F; Chang B; Gururaja TL; Xu W; Baluom M; Sweeny D; Carroll D; Sran A; Thota S; Parmer M; Romane A; Clemens G; Grossbard E; Qu K; Jenkins Y; Kinoshita T; Taylor V; Holland SJ; Argade A; Singh R; Pine P; Payan DG; Hitoshi Y
J Cancer Res Clin Oncol; 2010 Jan; 136(1):99-113. PubMed ID: 19609559
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design.
Dodson CA; Kosmopoulou M; Richards MW; Atrash B; Bavetsias V; Blagg J; Bayliss R
Biochem J; 2010 Mar; 427(1):19-28. PubMed ID: 20067443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
